NTLA240719C30000
- 0.08
- -0.02-20.00%
Intellia Therapeutics Newsroom
Stifel Nicolaus Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Maintains $73 Price Target
Intellia Therapeutics Analyst Ratings
Intellia Therapeutics Analyst Ratings
Truist Securities Maintains Buy on Intellia Therapeutics, Maintains $120 Price Target
Cantor Fitzgerald Reiterates Overweight on Intellia Therapeutics, Maintains $65 Price Target
Intellia Therapeutics Analyst Ratings
Intellia Therapeutics Analyst Ratings
JMP Securities Remains a Hold on Intellia Therapeutics (NTLA)
Oppenheimer Keeps Their Buy Rating on Intellia Therapeutics (NTLA)
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Liquidia Technologies (LQDA) and Pacific Biosciences (PACB)
Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Iovance Biotherapeutics (IOVA) and Intellia Therapeutics (NTLA)
Citi: Maintains Intellia Therapeutics (NTLA.US) rating, adjusted from neutral to neutral, and adjusted the target price from $31.00 to $29.00.
Intellia Therapeutics Analyst Ratings
Citigroup Maintains Neutral on Intellia Therapeutics, Lowers Price Target to $29
Bank of Montreal, Canada: Maintaining the Intellia Therapeutics (NTLA.US) rating, adjusted from superior to superior market rating, target price adjusted from $62.00 to $70.00.
Intellia Therapeutics Analyst Ratings
BMO Capital Maintains Outperform on Intellia Therapeutics, Raises Price Target to $70
Intellia Therapeutics: A Promising Buy Rating Supported by Trial Success and Strong Financials
Analysts' Opinions Are Mixed on These Healthcare Stocks: Catalyst Pharma (CPRX), Xenon (XENE) and Intellia Therapeutics (NTLA)